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Abstract: The aim of this study was to determine the seroprevalence of HCV in HBsAg positive subjects. In 
a population based single stage cluster sampling in Golestan province of Iran, 139 HBsAg positive subjects 
were detected and enrolled in the study. Serum samples were tested using ELISA method for anti-HCV 
antibodies. Chi-square and Fisher's exact tests were used to compare the proportions. There were 68(48.9%) 
male and 71 (51.1 % ) female. The mean age was 41.89±11.30 years (25-64 years). One case was excluded because 
of inadequate blood sampling. Anti-HCV antibody was positive in 17(12.3%) of 138 remaining subjects. 
Seropositivity of HCV in female was higher than male (14.1 % versus 10.4%, respectively) but the difference was 
not statistically significant (p = 0.52). No significant relationship was seen between Anti-HCV seroprevalence 
and demographic factors such as age, place of residence and marital status. The seroprevalence of co-infection 
with HBV and HCV in our study was higher than such reports from some colllltries (Italy); but it was in line with 
worldwide prevalence (> 10% ). A careful longitudinal evaluation of the viremia levels of both HBV!HCV viruses 
is essential for making a correct diagnosis and tailoring the appropriate therapeutic schedule in co-infected 
patients. 
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INTRODUCTION 	
Hepatitis B and hepatitis C viruses are the most 
common causes of chronic liver disease (Crockett and 
Keefe, 2005). Approximately 350 million people are 
infected with HBV worldwide (Lee, 1997). The prevalence 
of HBV infection is generally higher in Asia and Africa 
than other parts of the world (Blum et al., 1998). More 
than 3% of Iranian populations are infected with HBV 
(Massarat et al., 2000). The World Health Organization 
estimates that approximately 1 70 million people are 
infected with HCV. Chroinc HBV and/or HCV infection 
may produce both cirrhosis and complicated by 
hepatocellular carcinoma (HCC). 
As hepatitis B virus (HBV) and hepatitis C virus 
(HCV) have the same transmission routs, dual infection 
may occur (Liaw, 2002). In areas of high prevalence of 
HBV infection such as Asian colllltries, the phenomenon 
of HCV super-infection is well described (Liaw, 2002; 
Liaw et al., 2004). 
Patients co-infected with both HBV and HCV may 
have more severe liver disease (Benvegnu et al., 1994; 
Kaklarnani et al., 1991). Some studies have suggested an 
increased risk of fulminant hepatitis with HCV and HBV 
co-infection (Chu et al., 1994; Wu et al., 1994). Co­
infected patients have also higher rates of cirrhosis 
(Fong et al., 1991). Dual infection withHBV andHCV has 
been shown in many case-control studies to correlate with 
an increased risk of developing HCC (Kaklamani et al., 
1991; Mohamed Ael et al., 1997). The mortality rate of 
HCV co-infection in chronic hepatitis B patients may be as 
high as 10% (Liaw, 2002). Therefore, it is very important to 
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identify whether a patient with HBV infection has co­
infected with HCV. Present study was conducted to 
determine the seroprevalence of HCV in HBsAg positive 
cases. 
MATERIALS AND METHODS 
A population based cross-sectional study had been 
conducted in Golestan province of Iran during 2004 to 
2005. A total sample size of 1850 subjects had been 
enrolled using a single stage cluster sampling method. To 
achieving this sample, 92 clusters had been selected using 
a systemic random sampling according to last census tract 
in Golestan province of Iran (2004-2005). In each cluster, 
20 subjects had been explored for hepatitis B virus surface 
antigen using ELISA kit, Diasorin, Italy (Sensitivity: 
100%; Specificity: 98.8% ). 164 (8.9%) ofl 850 subjects had 
been positive for HBsAg. Unfortllllately, the serum 
samples of 25 HBsAg positive subjects were inadequate 
or had been lost during the sampling phase. Therefore, 
139 of the HBsAg positive subjects were enrolled in our 
study. Approximately 2 mL blood was drawn from each 
case. Separation of serum was done llllder complete 
aseptic condition and then stored at -70°C lllltil use. The 
serological tests were performed using commercially 
available ELISA method according to the instructions 
provided in the manufacturer's manual. Anti-HCV 
antibody was detected using ELISA method (DRG, 
Germany). All data were analyzed by SPSS (Chicago, IL) 
software, version 12. Proportions were compared by 
Chi-square and Fisher's exact tests. P values of less than 
0.05 were considered significant. 
RESULTS 
Participants in the study were 68 (48.9%) males and 
71 (51.1 %) females. The mean age was 41.89±11.30 years 
(25-64 years). Demographic characteristics of the subjects 
are summarized in Table 1. One case was excluded 
because of inadequate blood sampling. Anti-HCV 
antibody was positive in 17 (12.3%) of 138 remaining 
Table 1: Demographic characteristics ofHBsAg positive cases in Golestan, 
Irnn 
Variables No. of cases (%2 
Sex Male 68(489) 
Female 71(51.1) 
Age groups 25-34 44(31. 7) 
35-44 32(23.0) 
45-54 40(288) 
55-65 23(16.5) 
Marital status Married 119(85.6) 
Single 20(14.4) 
Place of residence Rural area 53(3810) 
Urban area 86(61.92 
subjects. Ten females (14.1%) and 7 males (10.4%)were 
positive for Anti-HCV antibody; but the difference was 
not significant (p ~ 0.51; odds ratio~ 1.4, 95%CI: 0.5-3.9). 
The prevalence ofHCV seropositivity in rural population 
was higher than urban population (15.4% versus 10.5%); 
but it was not significant statistically. Seroprevalence of 
hepatitis C virus did not significantly differ between age 
groups. "When recategorizing the age variable into two 
groups based on median (42 years), the prevalence in 
younger cases (10%) was lower than older (14. 7% ), but 
there was still no significant difference (p = 0.4; odds 
ratio= 0.64, 95% CI: 0.23-1.8). There were no significant 
relationship between marital status and HCV 
seropositivity. 
DISCUSSION 
We conducted a seroepidemiological survey of co­
infection with hepatitis C virus in 139 apparently healthy 
HBsAg positive individuals living in Golestan province 
(northeast part) of Iran. 12.3% of participants were anti­
HCV antibody positive. This is higher than reports from 
some other studies. HCV seropositivity among HBsAg 
positive cases was reported as 2.7% by Barros et al. 
(1994) from Portugal. Gaeta et al. (2003) had detected anti­
HCV antibody in 7% of HBsAg positive subjects in Italy 
(2003). Seroprevalence of HCV in the same population 
from Taiwan was 8% (Chu et al., 1998). In another 
similar study, anti-HCV was positive in 9.8% of cases 
(Fattovich et al., 1991 ). In contrast with these studies, 
de Miguel et al. (1994) from Spain had detected anti­
HCV antibody in 16% of HBV infected subjects 
(higher prevalence rate than ours). 
The reported series of seroprevalence of HCV 
indicate that HCV is folllld in more than 10% of HBV­
infected patients world wide (Liaw, 2002); so they were in 
conformity with findings of present study. In present 
study, the seropositivity of HCV in females were higher 
than males; but Banos et al. (1994) inversely had reported 
a higher prevalence rate in males. 
In conclusion, Co-infection with HBV and HCV is 
common, especially in this area with a relatively high 
prevalence of hepatitis B. Dual infections present mrique 
management challenges given the complex interaction of 
HBV and HCV and the propensity for developing more 
severe liver disease. Caution must be exercised in treating 
co-infected patients, as flares of the lllltreated virus may 
occur. No standard of care has been established for 
treatment of co-infected patients and larger randomized, 
controlled trials are needed to clarify the optimal treatment 
for such patients and the role of newer antiviral agents. 
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